Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection.

Fountain FF, Tolley EA, Jacobs AR, Self TH.

Am J Med Sci. 2009 May;337(5):317-20. doi: 10.1097/MAJ.0b013e31818c0134.

PMID:
19295414
2.
3.

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ; Terry Beirn Community Programs for Clinical Research on AIDS; Adult AIDS Clinical Trials Group; Centers for Disease Control and Prevention.

Clin Infect Dis. 2004 Aug 15;39(4):561-5. Epub 2004 Jul 30.

PMID:
15356822
4.

[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].

Kaneko Y, Nagayama N, Kawabe Y, Shimada M, Suzuki J, Kunogi M, Matsui Y, Kawashima M, Suzuki J, Ariga H, Oshima N, Masuda K, Matsui H, Nagai H, Tamura A, Akagawa S, Toyoda E, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2008 Jan;83(1):13-9. Japanese.

PMID:
18283910
6.

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.

7.

Antituberculosis drug-induced hepatotoxicity: a comparison between patients with and without human immunodeficiency virus seropositivity.

Coca NS, Oliveira MS, Voieta I, Antunes CM, Lambertucci JR.

Rev Soc Bras Med Trop. 2010 Nov-Dec;43(6):624-8.

8.

Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.

Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, Memish Z, Khan K, Gardam M, Hoeppner V, Benedetti A, Schwartzman K.

Ann Intern Med. 2008 Nov 18;149(10):689-97.

PMID:
19017587
9.

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.

Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD.

Am J Respir Crit Care Med. 2003 Mar 15;167(6):824-7. Epub 2002 Nov 21.

PMID:
12446275
10.

Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.

Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD.

AIDS. 2007 Jun 19;21(10):1301-8.

PMID:
17545706
11.

National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.

McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, Navin TR.

Clin Infect Dis. 2005 Oct 15;41(8):1125-33. Epub 2005 Sep 9. Erratum in: Clin Infect Dis. 2006 Jan 15;42(2):313.

PMID:
16163632
12.

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC; Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.

Ann Intern Med. 2002 Oct 15;137(8):640-7.

PMID:
12379063
13.
14.
15.

Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.

Saito Z, Kaneko Y, Kinoshita A, Kurita Y, Odashima K, Horikiri T, Yoshii Y, Seki A, Seki Y, Takeda H, Kuwano K.

BMC Infect Dis. 2016 Nov 11;16(1):668.

16.

Liver injury during antituberculosis treatment: an 11-year study.

Døssing M, Wilcke JT, Askgaard DS, Nybo B.

Tuber Lung Dis. 1996 Aug;77(4):335-40.

PMID:
8796249
17.

Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.

Cook PP, Maldonado RA, Yarnell CT, Holbert D.

Clin Infect Dis. 2006 Aug 1;43(3):271-5. Epub 2006 Jun 22.

PMID:
16804838
18.

Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.

Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ.

Chest. 2005 Apr;127(4):1304-11.

PMID:
15821209
19.

Hepatotoxicity of pyrazinamide: cohort and case-control analyses.

Chang KC, Leung CC, Yew WW, Lau TY, Tam CM.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1391-6. doi: 10.1164/rccm.200802-355OC. Epub 2008 Apr 3.

PMID:
18388355
20.

Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.

Potolidis E, Mantadakis E, Zeniodi MH, Samonis G.

Scand J Infect Dis. 2005;37(2):155-7.

PMID:
15773037

Supplemental Content

Support Center